Wire · opportunities
Capricor shares soar as potential FDA lifeline revives Duchenne drug hopes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
Capricor Therapeutics' shares surged 70% after the FDA agreed to review new 24-month data on its Duchenne muscular dystrophy drug, deramiocel, potentially delaying the approval decision. This follows the FDA advisory panel's earlier rejection of the drug's initial effectiveness data due to trial outcome measurement concerns.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 14 Aug 2026 and 25 Aug 2026.
◆ ◆ The Wire takeaway
You face an unexpected opportunity as the FDA reopens review of Capricor's drug data, extending approval timelines and potentially shifting trial focus to upper limb benefits. Adjust your regulatory strategy to capitalise on extended review periods and evolving approval criteria in Duchenne therapies.
◆ Coverage
7 sources · first reported 14 Aug 2026 · latest 25 Aug 2026
◆ Related on Wire
◆ Topics